CD44 and cancer: Although CD44 is reported to be shed from the cell surface by MT1-MMP [62,64], it still was exploited for the creation of HA–drug bioconjugate carriers for selective delivery of various drugs such as paclitaxel, doxorubicin, camptothecin or cisplatin to cancer cells [65,66].